Summary
83 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 83 INR is left as net profit.
- Revenue grew by 99% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (Drug Manufacturers - Specialty & Generic)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 3.9 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (INR)
Diluted EPS (INR)
Revenue grew by 49% a year over 5 years. Over the last 3 years it grew by 99% a year.
Growth in detailDoes it make money?
Very wellWhere 100 INR of revenue goes
- Cost of sales 6.7 INR
- Research and development 1.6 INR
- Sales and administration 7.5 INR
- Taxes and other 1.2 INR
- Net profit 83 INR
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 2.0 INR
Out of every 100 INR of revenue, 83 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail